Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578435 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00578435: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00578435 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00578435, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine and confirm the role of bone marrow transplantation in the treatment of disorders of the red cell and hemoglobin including sickle cell anemia, thalassemia and diamond blackfan anemia.
Interventions
- PROCEDURE Busulfan, Cyclophosphamide, BMD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1994-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00578435
The ClinicalTrials.gov registry entry for NCT00578435 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Busulfan, Cyclophosphamide, BMD is the first listed.
NCT00578435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00578435 about?
NCT00578435 is a clinical study titled "Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis". The purpose of this study is to determine and confirm the role of bone marrow transplantation in the treatment of disorders of the red cell and hemoglobin including sickle cell anemia, thalassemia and diamond blackfan anemia.
What is the current status of trial NCT00578435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1994-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00578435?
The interventions under investigation include: Busulfan, Cyclophosphamide, BMD (PROCEDURE).
Who is sponsoring clinical trial NCT00578435?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.